As Sanofi Exits Diabetes R&D, Meaning Of ‘Diabetes R&D’ Blurs

Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.

Vials of drugs with syringes

Sanofi’s emphatic exit from diabetes research comes as the field is expanding beyond a focus on glucose levels to test for cardiovascular and renal benefits – an endeavor that requires very large, very expensive clinical outcomes trials in a crowded market that leaves little room for error.

That Sanofi, a long-time diabetes stalwart, is leaving the arena is one of the most remarkable signs of the stresses...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet